Curated and continually updated content to advance the science and treatment of IBD

Select reference articles in IBD, including research into the role of sphingosine-1-phosphate (S1P) metabolism

Novel and emerging therapies for inflammatory bowel disease

Al-Bawardy B, Shivashankar R, Proctor DD. Front Pharmacol. 2021;12:651415.

---

Reviews novel treatment agents currently in development.

A comprehensive review and update on the pathogenesis of inflammatory bowel disease

Guan Q. J Immunol Res. 2019;2019:7247238.

---

Reviews recent advances for development of new IBD therapies.

A review of the diagnosis, prevention, and treatment methods of inflammatory bowel disease

Seyedian SS, Nokhostin F, Malamir MD. J Med Life. 2019;12(2):113-122.

---

Reviews the pathophysiology of IBD, including Crohn’s disease and ulcerative colitis.

Mechanism-based treatment strategies for IBD: cytokines, cell adhesion molecules, JAK inhibitors, gut flora, and more

Schreiner P, Neurath MF, Ng SC, et al. Inflamm Intest Dis. 2019;4(3)79-76.

---

A review of the inflammatory signaling pathways in IBD and current and future therapeutic approaches to inhibiting them.

Focus on current and future management possibilities in inflammatory bowel disease–related chronic pain

Zielińska A, Sałaga M, Włodarczyk M, Fichna J. Int J Colorectal Dis. 2019;34(2):217-227.

---

Describes the relationship between IBD and the development of visceral chronic pain and its effects on patient quality of life.

Current perspectives on the diagnosis and management of functional anorectal disorders in patients with inflammatory bowel disease

Nigam GB, Limdi JK, Vasant DH. Therap Adv Gastroenterol. 2018;11:1756284818816956.

---

Reviews the current perspective on diagnosis and management of anorectal sensitivity, motility, and neuromuscular coordination in patients with IBD.

Targets for health interventions for inflammatory bowel disease–fatigue

Artom M, Czuber-Dochan W, Sturt J, Norton C. J Crohns Colitis. 2016;10(7):860-869.

---

Explores the potentially modifiable factors contributing to IBD fatigue and describes advances in fatigue management in patients with IBD.

Ulcerative colitis: an update

Segal J, LeBlanc JF, Hart AL. Clin Med (Lond). 2021;21(2):135-139.

---

Discusses currently available therapeutic options and the potential for personalized treatment.

Ulcerative colitis: recent advances in the understanding of disease pathogenesis

Porter JR, Kalla R, Ho GT. F1000Res. 2020;9:F1000 Faculty Rev-294.

---

Reviews novel developments in understanding the pathogenesis of UC.

Ulcerative colitis: understanding its cellular pathology could provide insights into novel therapies

Kaur A, Goggolidou P. J Inflamm (Lond). 2020;17:15.

---

Reviews the pathophysiology of ulcerative colitis to identify potential targets for therapy and help manage the condition.

International perspectives on management of inflammatory bowel disease: opinion differences and similarities between patients and physicians from the IBD GAPPS survey

Rubin DT, Sninsky C, Siegmund B, et al. Inflamm Bowel Dis. 2021;27(12):1942-1953.

---

Discusses the results of a survey of over 2300 patients with IBD and 650 physicians regarding education about disease remission and expectations for current therapies.

A qualitative research for defining meaningful attributes for the treatment of inflammatory bowel disease from the patient perspective

Louis E, Ramos-Goñi JM, Cuervo J, et al. Patient. 2020;13(3):317-325.

---

Analyzes the ten most relevant attributes that influence patient decisions when making treatment choices for IBD.

Patients perceive biologics to be riskier and more dreadful than other IBD medications

Koliani-Pace JL, Haron AM, Zisman-Ilani Y, Thompson KD, Siegel CA. Inflamm Bowel Dis. 2020;26(1):141-146.

---

A cross-sectional study at a single tertiary care center reveals patient perceptions of biologic therapies for IBD.

Patient and physician preferences for ulcerative colitis treatments in the United States

Boeri M, Myers K, Ervin C, et al. Clin Exp Gastroenterol. 2019;12:263-278.

---

Identifies the treatment attributes that both patients and physicians consider most important when making decisions on UC treatment.

National differences in ulcerative colitis experience and management among patients from five European countries and Canada: an online survey

Schreiber S, Panés J, Louis E, Holley D, Buch M, Paridaens K. J Crohns Colitis. 2013;7(6):497-509.

---

Reports results from an international survey of patients with UC and health care professionals involved in the care of patients with UC to explore existing gaps in the management of UC.

Targeting sphingosine-1-phosphate signaling in immune-mediated diseases: beyond multiple sclerosis

Pérez-Jeldres T, Alvarez-Lobos M, Rivera-Nieves J. Drugs. 2021;81(9):985-1002.

---

Evaluates S1P modulators as a therapeutic strategy for immune-mediated diseases.